2.4.0.8112 - Disclosure - Restricted Cashtruefalsefalse1falsefalsefalseeol_PE10315---1310-Q0011_STD_181_20130630_0http://www.sec.gov/CIK0001069308duration2013-01-01T00:00:002013-06-30T00:00:001false4opxa_DisclosureOfRestrictedCashAndCashEquivalentsTextBlockopxa_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Note 4.  Restricted Cash</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant
to the July 2012 Note financing, $1.0 million of the gross proceeds
were initially required to be maintained in a segregated account
and subject to a deposit control agreement while the July 2012
Notes are outstanding.  Pursuant to a waiver executed by
the holders of in excess of two-thirds (66-2/3%) of the principal
amount of the outstanding July 2012 Notes and accepted by Opexa,
the amount of the cash subject to the deposit control agreement was
reduced to $500,000 on January 29, 2013.  In exchange for
such waiver, the Company issued warrants to the holders of the July
2012 Notes to purchase an aggregate of 187,500 shares of the
Company’s common stock (see Note 10).  As of June
30, 2013, the $500,000 balance in the controlled account is
reported as restricted cash in the consolidated balance
sheets.</font></div>
</div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of Restricted Cash and Cash Equivalents.No definition available.false0falseRestricted CashUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfRestrictedCashAndCashEquivalentsTextBlock11